Clinical trials
Locally Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting locally advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 4,273 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07258563Recruiting
Can a special diet prevent taste changes from chemo?
This study looks at whether a special diet can help prevent taste changes during chemotherapy. It is for people with certain cancers who are about to start treatment.
AmsterdamAges 18–70 - NCT07258108RecruitingPhase 2
Sac-TMT and KL-A167 for HR+/HER2- Breast Cancer
This trial is testing a combination of two drugs, Sac-TMT and KL-A167, in people with a certain type of advanced breast cancer (HR+/HER2-) that is PD-L1 positive. It's for those whose cancer has gotten worse after treatment with a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18–75 - NCT07235176RecruitingPhase 1/Phase 2
QLS1304 plus hormone therapy for ER+ breast cancer
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
ShanghaiAges 18 years+ - NCT07227012RecruitingPhase 1/Phase 2
Study of a new drug for advanced liver cancer
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Irvine, CaliforniaAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT05508347RecruitingPhase 2
Testing a new antibody with chemo for locally advanced throat cancer
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
Chengdu, SichuanAges 18–70 - NCT06258304RecruitingPhase 1
Testing a new immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Bethesda, MarylandAges 18 years+ - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-low breast cancer
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
Largo, FloridaAges 18 years+ - NCT06313983RecruitingPhase 3
Study of hemay022 plus hormone therapy for advanced breast cancer
This trial tests a new targeted drug (hemay022) combined with an aromatase inhibitor (a type of hormone therapy) for people with advanced breast cancer that is both hormone-receptor-positive and HER2-positive. It may be an option if you've already tried trastuzumab or a similar treatment and it stopped working.
BeijingAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Anchorage, AlaskaAges 18 years+ - NCT07169994RecruitingPhase 1/Phase 2
Testing YL202 with other cancer treatments for advanced solid tumors
This trial is testing a new drug called YL202 in combination with other anti-cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if this combination can shrink tumors or slow their growth.
Hefei, AnhuiAges 18–75 - NCT07168200RecruitingPhase 3
Study of Adebrelimab with Chemoradiation for Advanced Cervical Cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07164976RecruitingPhase 1/Phase 2
Ribociclib for advanced HR+ HER2- breast cancer
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
NagoyaAges 18 years+ - NCT06207734RecruitingPhase 2
Stopping CDK4/6 inhibitors in advanced breast cancer
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
BerlinAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07108309RecruitingPhase 2
Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
BrestAges 18–74 - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT04947189RecruitingPhase 1/Phase 2
Seviteronel plus chemo for advanced triple-negative breast cancer
This trial tests seviteronel together with standard chemotherapy to treat certain types of advanced breast cancer that has spread. It’s looking to see how well the combination works and how safe it is, especially for cancers that are androgen-receptor positive.
Darlinghurst, New South WalesAges 18 years+ - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70
Hear when a new Locally Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 4,273 recruiting locally advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced/Metastatic Breast Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Advanced or Metastatic Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.